Journal of Jilin University(Medicine Edition) ›› 2022, Vol. 48 ›› Issue (2): 513-517.doi: 10.13481/j.1671-587X.20220231

• Clinical medicine • Previous Articles     Next Articles

Bronchopleural fistula complicated in treatment process of non-small cell lung cancer by bevacizumab combined with paclitaxel: A case report and literature review

Junjie HOU1,2,Xuguang MI1,Xiaonan LI1,Xiaonan LI2,Ying YANG1,Xianzhuo JIANG1,Ying ZHOU1,Zhiqiang NI1,Ningyi JIN2,3,Yanqiu FANG1()   

  1. 1.Department of Comprehensive Oncology,Jilin Province People’s Hospital,Changchun 130021,China
    2.Department of Pathophysiology,School of Medical Sciences,Yanbian University,Yanji 133002,China
    3.Laboratory of Molecular Virology and Immunology,Academy of Military Medical Sciences,Changchun 130122,China
  • Received:2021-08-26 Online:2022-03-28 Published:2022-05-10
  • Contact: Yanqiu FANG E-mail:yq.fang@163.com

Abstract: Objective

To investigate the possible mechanism, clinical manifestations and prevention strategies of bronchopleural fistula (BPF) complicated in the treatment of non-small cell lung cancer (NSCLC) by bevacizumab combined with paclitaxel (albumin-binding type),and to identify the individuals with potential risk in time,and to provide the reference for the prevention of this disease.

Methods

The clinical data of one patient with bronchopleural fistula(BPF) complicated in the treatment of NSCLC by bevacizumab combined with paclitaxel (albumin binding type) were collected,and the relevant literatures were reviewed and the potential risk of occurrence was summarized.

Results

A 62-year-old male patient with locally advanced lung adenocarcinoma (negative drive gene) was administered with bevacizumab and paclitaxel (albumin bound) chemotherapy. After 2 cycles of chemotherapy, the patient’s clinical symptoms and functional status were improved. However, due to acute BPF and secondary intrathoracic infection, the patient was forced to stop anti-angiogenic therapy and chemotherapy. Although closed thoracic drainage, active anti-infection treatment and optimal supportive treatment were performed,the clinical symptoms were not relieved.The patient died of respiratory failure on September 17, 2019.

Conclusion

Acute BPF should be induced when the lesions invades pleura, trachea and chest wall simultaneously, and the tumor cavitation effect occurred during the treatment of bevacizumab combined with chemotherapy or the tumor cavity existed in the lesions before treatment.Due to the lack of effective prevention and treatment measures for acute BPF,timely identification of the individual patients with potential risks is crucial to the prognosis.

Key words: Bevacizumab, Bronchopleural fistula, Cancer,non-small cell lung, Anti-angiogenesis, Chemotherapy

CLC Number: 

  • R734.2